You may have read that there are no medicines for fatty liver. That blanket statement is outdated.
In the United States, approved treatments are available for selected adults with MASH and moderate-to-advanced fibrosis. This does not mean everyone whose scan mentions fatty liver needs—or qualifies for—these medicines.
The first step is understanding your diagnosis and fibrosis assessment. This guide explains the main distinctions and the questions to discuss with your prescriber.
Approval information checked October 12, 2026. Availability and authorized uses can differ outside the United States.
Considering an additional educational resource? View the Fatty Liver Solution program and review its contents, claims and purchase terms. An educational guide cannot determine medication eligibility.
Affiliate disclosure: This article contains affiliate links. We may earn a commission if you purchase through them, at no additional cost to you.
Why “Fatty Liver” Is Not Enough to Choose a Medicine
Liver fat, inflammation and scarring are different findings.
MASH—previously called NASH—involves inflammation and liver-cell injury alongside liver fat. Fibrosis means scarring.
An ultrasound fat grade does not establish fibrosis stage or medication eligibility. Your clinician needs to interpret the wider assessment.
Read our fatty liver stages and fibrosis guide for background.
Approved Options to Discuss
| Medicine | US approval context | Important distinction |
|---|---|---|
| Rezdiffra, containing resmetirom | Adults with noncirrhotic NASH and moderate-to-advanced fibrosis, alongside diet and exercise | Not a general prescription for every fatty liver finding |
| Wegovy injection, containing semaglutide | Adults with MASH and moderate-to-advanced fibrosis | The approved product and indication matter; not every semaglutide product is interchangeable |
Ask the prescriber to check the current full prescribing information and your individual suitability.
Rezdiffra: What Should You Know?
The FDA approved Rezdiffra in March 2024 for its specified NASH population.
Its approval used trial evidence showing improvement in biopsy-based inflammation or fibrosis outcomes in a proportion of participants. It does not promise improvement for every patient.
FDA information identifies diarrhea and nausea among common side effects, plus precautions involving liver injury, gallbladder problems and drug interactions. Some statin regimens may require adjustment.
Bring your complete medication list. Ask which risks, interactions and monitoring apply to you rather than stopping another medicine yourself.
Wegovy: What Should You Know?
The FDA has approved Wegovy injection for MASH with moderate-to-advanced fibrosis.
Its supporting trial assessed biopsy outcomes alongside lifestyle changes. Response varied, and treatment is not a guaranteed cure.
Common adverse effects include digestive symptoms such as nausea, vomiting and diarrhea. FDA information also identifies contraindications including a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2.
Ask your clinician to explain the full safety information, suitability and treatment plan. Do not use an online article to select a dose or schedule.
What Does Accelerated Approval Mean?
Both approvals discussed here used the FDA’s accelerated approval pathway.
This allows earlier approval for serious conditions based on endpoints considered likely to predict clinical benefit, with further evidence required to confirm longer-term outcomes.
It is useful to distinguish improvement in biopsy findings from proof that treatment prevents every future liver complication.
Ask what benefits are established, what remains uncertain and how that affects the decision.
Does Everyone Need a Biopsy Before Treatment?
The appropriate diagnostic pathway depends on the medicine, current guidance and your findings.
Ask how your clinician will establish eligibility and whether additional assessment is needed. Do not assume you qualify from an ultrasound report or a self-calculated score.
Our fatty liver diagnosis guide explains the broader evaluation.
Medicines for Other Conditions Are Part of the Discussion
Your care may also include treatment for diabetes, weight-related conditions, cholesterol or other health problems.
Ask what each medicine is intended to treat. Approval for one purpose does not automatically establish approval for a different liver indication.
Keep a current list of prescriptions, nonprescription medicines and supplements. This helps the prescriber assess the complete regimen.
Looking for optional reading alongside your care? Review the Fatty Liver Solution program information. Check its medication-related claims against current medical guidance.
What About Vitamin E, Herbs or Supplements?
Do not assume that a nonprescription product is suitable because it is marketed for liver health.
NIDDK advises discussing supplements and complementary approaches with your clinician; some herbal products can damage the liver.
Ask about evidence, appropriate use, interactions and potential harm before starting. Our supplements for fatty liver guide addresses that separate topic.
Why Lifestyle Care Still Matters
The availability of medicines does not remove the role of food choices and physical activity.
NIDDK describes benefits from appropriate weight management and activity, including activity without weight loss. If weight loss is indicated, it recommends gradual progress.
Our fatty liver diet guide and exercise guide provide practical starting information.
Ask how these actions fit the proposed medicine rather than treating them as separate plans.
How to Evaluate a Treatment Recommendation
Before agreeing to treatment, clarify:
| Question | What you want explained |
|---|---|
| Why this medicine? | How it fits your diagnosis |
| What benefit is expected? | The outcome being targeted |
| What are the main risks? | Individual precautions and adverse effects |
| What interactions matter? | Changes needed to the complete regimen |
| How will we monitor it? | Tests, appointments and symptoms to report |
| What will it cost? | Access, coverage and ongoing expense |
| When will we review the decision? | How continuation will be assessed |
Ask for written instructions where useful.
Do Not Stop Treatment Based on One Better Result
A favorable result needs interpretation in the context of your treatment goals.
Ask whether it changes the plan. Do not stop or change prescribed medicines yourself because symptoms improve, weight decreases or a blood result enters the reference range.
Our signs fatty liver is improving guide explains why different measurements answer different questions.
Frequently Asked Questions
Are there approved medicines for fatty liver?
There are US-approved options for specified adults with MASH and fibrosis. That is different from a universal medicine for all liver-fat findings.
Does grade 2 fatty liver qualify me?
An ultrasound fat grade does not establish eligibility. Further assessment may be needed.
Is every semaglutide product approved for MASH?
Do not assume that. The exact product, formulation and authorized indication matter.
Can I replace prescribed treatment with a paid program?
An educational program cannot replace individualized treatment.
What if I live outside the United States?
Ask your clinician about local approvals, availability and prescribing guidance.
Start With Eligibility and a Clear Plan
Ask what has been diagnosed, whether you qualify for a specific treatment and how its benefits and risks apply to you.
Use medicines, lifestyle actions and monitoring as parts of one fatty liver care plan.
Interested in the optional paid resource? Visit the Fatty Liver Solution information page. Review its claims and purchase terms carefully; it cannot replace prescribing advice or guarantee recovery.
Resources
- FDA: Rezdiffra Approval for NASH With Fibrosis
- FDA: Wegovy Approval for MASH
- NIDDK: Diagnosis of Fatty Liver
- NIDDK: Lifestyle Treatment
Source note: The older NIDDK treatment page’s statement that no medicines are approved is outdated. The FDA sources above provide the approval information used here.
Medical disclaimer: This article provides general educational information and does not replace individualized prescribing, diagnosis or treatment.
5 thoughts on “Fatty Liver Medicines: Approved Options and Limitations”